The recruitment period for this trial is 3 years. To date 90 of the 350 patients required have joined the trial.
Recruitment: The trial opened on 16th December 2011. In previous studies the degree of activity and response rates reported has varied considerably so there is a need to investigate the role of hormonal therapies in selected women with potentially hormone responsive gynaecological cancers. Rationale for Treatment: Anastrozole is well tolerated compared to chemotherapy and can be administered for prolonged periods with relatively little cumulative toxicity. Treatment Given: 1 tablet (1 mg) anastrozole to be taken orally once daily. Patients Involved: Patients with recurrent or metastatic gynaecological cancers that are oestrogen receptor and/or progesterone receptor positive.
Trial Name: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms.
0 kommentar(er)
